Development and Validation of a Multivariable Nomogram Predictive of Post-Nephroureterectomy Renal Function.

IF 8.3 1区 医学 Q1 ONCOLOGY European urology oncology Pub Date : 2024-12-01 Epub Date: 2024-02-01 DOI:10.1016/j.euo.2024.01.005
Patrick J Hensley, Craig Labbate, Andrew Zganjar, Jeffrey Howard, Heather Huelster, Trey Durdin, Jonathan Pham, Lianchun Xiao, Maximilian Pallauf, Kara Lombardo, Ilya Glezerman, Nirmish Singla, Jay D Raman, Jonathan Coleman, Philippe E Spiess, Vitaly Margulis, Aaron M Potretzke, Surena F Matin
{"title":"Development and Validation of a Multivariable Nomogram Predictive of Post-Nephroureterectomy Renal Function.","authors":"Patrick J Hensley, Craig Labbate, Andrew Zganjar, Jeffrey Howard, Heather Huelster, Trey Durdin, Jonathan Pham, Lianchun Xiao, Maximilian Pallauf, Kara Lombardo, Ilya Glezerman, Nirmish Singla, Jay D Raman, Jonathan Coleman, Philippe E Spiess, Vitaly Margulis, Aaron M Potretzke, Surena F Matin","doi":"10.1016/j.euo.2024.01.005","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objective: </strong>The timing of perioperative nephrotoxic chemotherapy for upper tract urothelial carcinoma (UTUC) remains controversial and strongly depends on predicted platinum eligibility after radical nephroureterectomy (RNU). The study objective was to develop and validate a multivariable nomogram to predict estimated glomerular filtration rate (eGFR) following RNU.</p><p><strong>Methods: </strong>This was a multi-institutional retrospective study of patients with UTUC treated with RNU from 2000 to 2020 at seven high-volume referral centers. Use of adjuvant chemotherapy was risk-stratified. Patients were retrospectively randomly allocated 2:1 to discovery and validation cohorts. Discovery data were used to identify independent factors associated with GFR at 1-3 mo after RNU on linear regression, and backward selection was applied for model construction. Accuracy was defined as the percentage of predicted eGFR results within 30% of the corresponding observed eGFR.</p><p><strong>Key findings and limitations: </strong>We included 1100 patients, of whom 733 were in the discovery and 367 were in the validation cohort. Multivariable predictors of postoperative eGFR decline included advanced age (odds ratio [OR] -0.18, 95% confidence interval [CI] -0.28 to -0.08), diabetes (OR -2.38, 95% CI -4.64 to -0.11), and hypertension (OR -2.24, 95% CI -4.16 to -0.32). Factors associated with favorable postoperative eGFR included larger tumor size (OR 10.57, 95% CI 7.4-13.74 for tumors >5 cm vs ≤2 cm) and preoperative eGFR (OR 0.44, 95% CI 0.39-0.49). A composite nomogram predicted postoperative eGFR with good accuracy in both the discovery (80.5%) and validation (78.6%) cohorts. Limitations include exclusion of patients who received neoadjuvant chemotherapy.</p><p><strong>Conclusions: </strong>A nomogram that incorporates ubiquitous preoperative clinical variables can predict post-RNU eGFR and was validated with an independent cohort.</p><p><strong>Patient summary: </strong>We developed a tool that uses patient data to predict eligibility for chemotherapy after surgery to remove the kidney and ureter in patients with cancer in the upper urinary tract.</p>","PeriodicalId":12256,"journal":{"name":"European urology oncology","volume":" ","pages":"1313-1319"},"PeriodicalIF":8.3000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European urology oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.euo.2024.01.005","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/1 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background and objective: The timing of perioperative nephrotoxic chemotherapy for upper tract urothelial carcinoma (UTUC) remains controversial and strongly depends on predicted platinum eligibility after radical nephroureterectomy (RNU). The study objective was to develop and validate a multivariable nomogram to predict estimated glomerular filtration rate (eGFR) following RNU.

Methods: This was a multi-institutional retrospective study of patients with UTUC treated with RNU from 2000 to 2020 at seven high-volume referral centers. Use of adjuvant chemotherapy was risk-stratified. Patients were retrospectively randomly allocated 2:1 to discovery and validation cohorts. Discovery data were used to identify independent factors associated with GFR at 1-3 mo after RNU on linear regression, and backward selection was applied for model construction. Accuracy was defined as the percentage of predicted eGFR results within 30% of the corresponding observed eGFR.

Key findings and limitations: We included 1100 patients, of whom 733 were in the discovery and 367 were in the validation cohort. Multivariable predictors of postoperative eGFR decline included advanced age (odds ratio [OR] -0.18, 95% confidence interval [CI] -0.28 to -0.08), diabetes (OR -2.38, 95% CI -4.64 to -0.11), and hypertension (OR -2.24, 95% CI -4.16 to -0.32). Factors associated with favorable postoperative eGFR included larger tumor size (OR 10.57, 95% CI 7.4-13.74 for tumors >5 cm vs ≤2 cm) and preoperative eGFR (OR 0.44, 95% CI 0.39-0.49). A composite nomogram predicted postoperative eGFR with good accuracy in both the discovery (80.5%) and validation (78.6%) cohorts. Limitations include exclusion of patients who received neoadjuvant chemotherapy.

Conclusions: A nomogram that incorporates ubiquitous preoperative clinical variables can predict post-RNU eGFR and was validated with an independent cohort.

Patient summary: We developed a tool that uses patient data to predict eligibility for chemotherapy after surgery to remove the kidney and ureter in patients with cancer in the upper urinary tract.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
肾切除术后肾功能多变量预测提名图的开发与验证
背景和目的:上尿路上皮癌(UTUC)围术期肾毒性化疗的时机仍存在争议,并且在很大程度上取决于根治性肾切除术(RNU)后的铂金资格预测。研究目的是开发并验证一个多变量提名图,用于预测根治性肾切除术后的肾小球滤过率(eGFR):这是一项多机构回顾性研究,研究对象是 2000 年至 2020 年期间在七个高流量转诊中心接受 RNU 治疗的 UTUC 患者。对辅助化疗的使用进行了风险分层。患者以 2:1 的比例随机分配到发现组和验证组。发现数据用于确定与 RNU 后 1-3 个月时 GFR 相关的线性回归独立因素,并应用反向选择构建模型。准确性的定义是预测的 eGFR 结果与相应观察到的 eGFR 结果的百分比在 30% 以内:我们纳入了 1100 名患者,其中 733 人属于发现队列,367 人属于验证队列。术后 eGFR 下降的多变量预测因素包括高龄(比值比 [OR] -0.18,95% 置信区间 [CI] -0.28 至 -0.08)、糖尿病(比值比 -2.38,95% 置信区间 [CI] -4.64 至 -0.11)和高血压(比值比 -2.24,95% 置信区间 [CI] -4.16 至 -0.32)。与良好的术后 eGFR 相关的因素包括肿瘤尺寸较大(肿瘤大于 5 厘米与小于 2 厘米的 OR 值为 10.57,95% CI 为 7.4-13.74)和术前 eGFR(OR 值为 0.44,95% CI 为 0.39-0.49)。在发现队列(80.5%)和验证队列(78.6%)中,复合提名图预测术后 eGFR 的准确率都很高。局限性包括排除了接受新辅助化疗的患者:患者摘要:我们开发了一种工具,利用患者数据预测上尿路癌症患者在手术切除肾脏和输尿管后接受化疗的资格。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
15.50
自引率
2.40%
发文量
128
审稿时长
20 days
期刊介绍: Journal Name: European Urology Oncology Affiliation: Official Journal of the European Association of Urology Focus: First official publication of the EAU fully devoted to the study of genitourinary malignancies Aims to deliver high-quality research Content: Includes original articles, opinion piece editorials, and invited reviews Covers clinical, basic, and translational research Publication Frequency: Six times a year in electronic format
期刊最新文献
Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data. Reply to Riccardo Leni, Andreas Roder, and Hein V. Stroomberg's Letter to the Editor re: Julien Anract, Clément Klein, Ugo Pinar, Morgan Rouprêt, Nicolas Barry Delongchamps, Grégoire Robert. Incidental Prostate Cancer in Patients Undergoing Surgery for Benign Prostatic Hyperplasia: A Predictive Model. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2024.08.009. Longitudinal Assessment of Cognitive Function in Survivors of Testicular Germ Cell Tumor. Early Oncological Outcomes in Patients who Underwent Staging Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging Before Radical Prostatectomy and Extended Pelvic Lymph Node Dissection. Oncologic Outcomes of Sequential Intravesical Gemcitabine and Docetaxel Compared with Bacillus Calmette-Guérin in Patients with Bacillus Calmette-Guérin-Unresponsive Non-Muscle Invasive Bladder Cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1